Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy

Mizutani, Kosuke; Horie, Kengo; Kato, Taku; Nakane, Keita; Kawakami, Kyojiro; Fujita, Yasunori; Ito, Masafumi

doi:10.1007/s00432-018-2806-2

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 The anti-PD-1 monoclonal antibodies pembrolizumab and nivolumab were approved by the Food and Drug Administration (FDA) in 2014, and have achieved satisfactory results in melanoma, non-small cell lung cancer (NSCLC), renal cell cancer (RCC) and other malignant tumors. [18][19][20] However, most patients do not respond optimally to the immune checkpoint blockade (ICB), and some are completely unresponsive. Therefore, a better understanding of the pathways and molecular mechanisms that block the PD-1/PD-L1 pathway is needed.…”

Section: Introductionmentioning

confidence: 99%

<p>EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer</p>

Zhou

Liu

Song

et al. 2020

CMAR

View full text Add to dashboard Cite

To investigate the anti-tumor effects of programmed cell death protein 1 (PD-1) scFv-secreting EGFR-chimeric antigen receptor-modified (CAR)-T cells against gastric cancer. Methods: Second-generation EGFR-CART cells and fourth-generation PD-1 scFvsecreting EGFR-CART cells were engineered. The anti-tumor activities of chimeric antigen receptor-modified (CAR)-T cells were analyzed in vitro by long-term co-culture with gastric cancer cells. The tumor scavenging capacity in vivo was evaluated in xenograft and PDX mouse models. Results: EGFR-CART cells secreting PD-1 scFv showed enhanced long-term tumor cell killing capacity in vitro. These cells also showed significant anti-tumor effect in the subcutaneous xenograft model of gastric cancer as well as in the PDX model, and autocrine PD-1 antibody secretion significantly increased tumor infiltration of the CART cells. Conclusion: EGFR-CART cells secreting PD-1 scFv are highly effective against gastric cancer and offer new insights into anti-cancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%